The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME)
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
Subscribe To Our Newsletter & Stay Updated
